Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients |
Jul 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
Jul 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag |
Jul 2020 |
Leukemia |
Aplastic Anemia |
Genetics of Progression From MDS to Secondary Leukemia |
Jul 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
Jul 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
Jul 2020 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Where There's Smoke, There's Fire: Inflammation Drives MDS |
Jul 2020 |
Trends in immunology |
Myelodysplastic Syndromes (MDS) |